Topas Therapeutics
PrivateLast Round
Series B
Jul 29, 2021
Total Funding Raised
$138M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Topas Therapeutics operates in Healthcare & Life Sciences and is based in Hamburg. Its latest recorded funding round was a Series B round in July 2021.
Topas Therapeutics is a biotechnology company that develops nanoparticle-based therapeutics to induce antigen-specific immune tolerance for the treatment of autoimmune diseases, allergies, and anti-drug antibodies.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Topas Therapeutics Comparables
Compare Topas Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Anokion | 90% | |
| Imcyse | 86% | |
| Cour Pharma | 85% |
For institutional investors. Book with your work email.
Topas Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jul 29, 2021 | ||||
| Series B | Oct 19, 2020 | ||||
| Series A | Nov 2, 2017 | ||||
| Series A | Mar 22, 2016 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Topas Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| BioMedPartners | Series B |
| Gimv | Series A, Series B |
| Epidarex Capital | Series A, Series B |
| Vesalius Biocapital Partners | Series B |
| Boehringer Ingelheim Venture Fund | Series A, Series B |
| EMBL Ventures | Series A, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 18, 2026
Presenting at BioCentury's Grand Rounds Europe on September 18, 2026.
- Oct 6, 2025
Presented new Phase 2a data for TPM502 at UEG Week.
For institutional investors. Book with your work email.
Topas Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Topas Therapeutics's valuation, stock price, and market status.
Is Topas Therapeutics a public or private company?
Topas Therapeutics is a private company.
What is the current stock price of Topas Therapeutics?
Topas Therapeutics is a private company, so its shares have no public market price. Caplight tracks Topas Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Topas Therapeutics worth (valuation)?
Valuation information for Topas Therapeutics is not publicly available.
Can I buy Topas Therapeutics stock?
Topas Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Topas Therapeutics's last funding round?
Topas Therapeutics's most recent funding round was Series B on July 29, 2021.
Who are the main investors in Topas Therapeutics?
Key investors in Topas Therapeutics include BioMedPartners, Epidarex Capital, Vesalius Biocapital Partners.
Will Topas Therapeutics IPO soon?
No public IPO plans have been announced for Topas Therapeutics.
How can I track Topas Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Topas Therapeutics's shares on secondary markets.